A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy
What is the purpose of this trial?
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
- Ages18 years and older
- GenderFemale only
- Trial withSynthon Biopharmaceuticals BV
- Start Date07/06/2020
- End Date04/01/2022
- Last Updated07/15/2021
- Study HIC#2000026973